DOCSLIB.ORG

Management of Abnormal Uterine Bleeding

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Abnormal Uterine Bleeding Disclosures July 4, 2017. I have no disclosures. Management of abnormal uterine bleeding Jody Steinauer, MD, MAS Dept. Ob/Gyn & Reproductive Sciences University of California, San Francisco The Questions Case 1 • Too much – abnormal uterine bleeding A 46 year‐old woman reports her periods have – Differential and approach to work‐up become increasingly irregular and heavy over the • Too much – fibroids last 6‐8 months. Sometimes they come 2 times per • Too fast: She’s hemorrhaging—what do I do? month and sometimes there are 2 months between. • Side effect: due to hormonal contraception LMP 2 months ago. She bleeds 10 days with clots and frequently bleeds through pads to her clothes. She also has diabetes and is obese. 1: AUB and 2: fibroids 3: Acute hemorrhage 4: Contraceptive side effects 5: Bleeding in pregnancy Q1: Which is the first test should you order in this patient? Step 1: Pregnant? 1. FSH Pregnant Not Pregnant 2. Testosterone & DHEAS • Ectopic • Anovulation *** 3. Urine hcg • Spontaneous Abortion • Anatomic/structural ** 4. TSH • Threatened Abortion • Neoplastic * 5. Transvaginal Ultrasound (TVUS) • Molar Pregnancy • Infectious 6. Endometrial Biopsy (EMB) • Trauma • Iatrogenic • Other causes • Non‐gynecologic * = Most likely for this patient Terminology: What is abnormal? Pathophysiology: Anovulatory Bleeding • Normal: Cycle= 28 days (21‐35); Length=2‐7 days; Bricks & Mortar heaviness=self‐defined Estrogen=Bricks, build endometrium • Too little bleeding: amenorrhea or oligomenorrhea Progesterone (P) =Mortar, stabilizes, • Too much bleeding: Menorrhagia (regular timing but heavy only have P if ovulate (according to patient or >80cc) OR long flow (>7 days) Normal menses: Withdrawal of P • Irregular bleeding: Metrorrhagia, intermenstrual or post‐ causes wall to fall down, all at once coital bleeding (orderly bleed) Anovulation: No P so when wall • Irregular and Excessive: Menometrorrhagia grows too tall, it falls. It is heavy when wall is tall. Bricks can also fall intermittently & incompletely – • Preferred term for non‐pregnant heavy and/or irregularly, irregular irregular bleeding = Abnormal Uterine Bleeding (AUB) Bradley, AJOG, 2016 Abnormal Uterine Bleeding Reference: AUB Differential PALM-COEIN Uterus: Polyp, adenomyosis, leiomyoma, atrophy Not Pregnant Cervix: polyp, atrophy, trauma Vagina: atrophy, trauma Anovulation Uterus: Hyperplasia, malignancy Cervix: Dysplasia, malignancy Anatomic Ovary: hormone producing tumor Neoplastic Uterus: Endometritis, PID Cervix: Cervicitis Infectious Vagina: Vaginitis (eg Trich) Non‐Gynecologic Coagulopathy (vWD), severe renal or liver dz, GI or GU source History and Physical Examination Initial Work‐up: Menometrorrhagia • Hx: bleeding pattern, symptoms of anemia, sexual & • Always: Urine pregnancy reproductive history, chronic medical illness, medication • Usually: TSH • Acute v. chronic • Maybe: Hct, r/o coagulopathy • PE: signs of hypovolemia and anemia, thyroid • Maybe: EMB (Endometrial Biopsy) examination, gynecologic exam, abdominal examination, • Maybe but later: Transvaginal Ultrasound (screening for cervical dysplasia and STI) – Obesity: up to 60% of women who do not ovulate are obese – • Usually not necessary: FSH, LH, Testosterone, increased estradiol & testosterone; elevated insulin Estradiol disordered follicular development Do all women with AUB need an A Rational Approach to EMB ultrasound? Post‐Menopause: ALL women WITH ANY BLEEDING (except 4‐6 months Although TVUS is the best imaging choice for pelvic after HT) pathology (ie better than MRI, CT)…. Recent onset irregular bleeding: Consider treating first and if bleeding normalizes, no need for EMB • 80% with heavy menstrual bleeding have no >50: All women with recurrent, irregular bleeding (consider not doing if anatomic pathology periods light and spacing out) 45‐50: Recurrent irregular bleeding plus >1 risk factor OR > 6 mos • Incidental findings such as functional ovarian cysts menometrorrhagia (consider not doing if periods light and spacing out) and small fibroids (~50%) are often found leading <45: Long hx (>2 yr?) of untreated anovulatory bleeding or failed medical to anxiety and unnecessary treatments management EMB is not perfectly sensitive so further evaluation mandatory if: • SO….treat first, TVUS if treatment fails 1. Persistent AUB after negative EMB 2. Persistent AUB after 3‐6 months of medical therapy What about U/S instead of EMB for post‐ TVUS vs EMB to Detect Cancer menopausal bleeding? (in post‐menopausal women) Transvaginal Ultrasound TVUS EMB • Measure endometrial stripe 96% Sensitivity 94% • Abnormal= >4 mm (or 5) 61% Specificity 99% • Non‐specific: myomas, polyps also cause thick EM 99% NPV 99% • Operator skill mandatory 40‐50% Further w/u ? <5% necessary • NOT USEFUL PRE‐MENOPAUSE Can offer patient choice as long as either is quickly available and patient understands she may need EMB after U/S Q2: You decide to do a urine pregnancy test and check Q2: You decide to do a urine pregnancy test and check her TSH – which is the most appropriate next test? her TSH –which is the most appropriate next test? 1. FSH 1. FSH A 46 year‐old woman reports her periods have become 2. Testosterone & DHEAS 2. Testosterone & DHEAS increasingly irregular and 3. Serum beta‐HCG 3. Serum beta‐HCG heavy over the last 6‐8 months. Sometimes they come 4. Transvaginal Ultrasound 4. Transvaginal Ultrasound 2 times per month and 5. Endometrial Biopsy 5. Endometrial Biopsy sometimes there are 2 months between. LMP 2 months ago. She bleeds 10 days with clots and frequently bleeds through pads to her clothes. She also has diabetes and is obese. EMB=“Disordered Proliferative” How do I stop the bleeding? Treatment of AUB: NSAIDs Medical Surgical • Suppress prostaglandin synthesis, increase platelet NSAID’s Endometrial ablation aggregation, and reduce menstrual blood loss E+P pill, patch, ring D&C/Hysteroscopy • Reduces blood loss by 40% Oral Progestin Hysterectomy • Use alone or with other treatments Progestin IUD • Prescribe 5 days ATC IM Progestin – Ibuprofen, mefenamic acid, naproxen GnRH agonist Tranexamic Acid Disordered proliferative= Anovulation Treatment of AUB: CHC Treatment of AUB: Progestins • CHC – pill, patch, ring – improve cycle control, • Oral progestin – If ovulatory AUB = HMB: daily or days 5‐26 “extended use” decrease menstrual blood loss by 40% when used progestin decreases blood loss traditionally or continuously (MPA 2.5‐10mg qd, norethindrone 2.5‐5mg qd, NETA 5 TID) – Low satisfaction with extended use – One COC (with estradiol) approved by FDA for heavy – If anovulatory: cyclic progestin ‐12‐14 d/month improves menstrual bleeding menses in half of women – COCs often used to treat acute and chronic AUB • Injectable progestin – Few studies support up to 70% decreased EBL with COC – 50% amenorrhea after 1 year, irreg. bleeding in first few months and 50% at one year and one study with vaginal ring • Intrauterine progestin – Significant decrease in blood loss, superior to other progestins and CHCs Bradley, AJOG, 2016 Bradley, AJOG, 2016; Heikinheimo, Best Practice & Research Clin Ob Gyn, 2017. First Line Hormonal Treatments Where do you find the US MEC and SPR? • First choice: Levonorgestrel IUD – >80% reduction in blood loss, decreased cramping, prevents/treats hyperplasia, highly effective birth control – Blood loss and satisfaction comparable to ablation, satisfaction comparable to hysterectomy – Very few contraindications • 2nd choice: combined contraceptives (pill, patch, ring) or oral progestin (cyclic v. daily) or progestin injection – Decreases irregular perimenopausal bleeding – Any type ok, 20 mcg estrogen preferred for women >40 – Estrogen contraindications: smokers>35, HTN, complicated DM, multiple RF for CAD, h/o DVT, migraines with aura Birth Control Methods Treatment of AUB: Tranexamic Acid • Approved by FDA for treatment of ovulatory AUB • Prevents plasma formation, fibrin degradation, and clot degradation • In RCT’s, more effective than placebo, NSAID, cyclic progestin Medical • Dose: 1.0‐1.3 g every 6‐8 hours x 5 days Condition • Risks: Theoretic risk of VTE – contraindicated in history of or risk factors for VTE – not with CHC • Side effects: Minimal MEC Category Perimenopausal/Anovulatory Bleeding: Surgical Treatments Summary • D&C, Hysteroscopy: R/o pregnancy, thyroid dz – Not really a treatment EMB if meets criteria – Temporary reduction in bleeding – Curative if fibroid or polyp removed Treat first as if anovulatory bleeding: – NSAIDs + • Endometrial Ablation – Hormones (Levo IUD, CHC, DMPA) – Reduces but doesn’t eliminate menses If persists: – ~25% repeat ablation or hysterectomy in 5 years – U/S to check for anatomic causes (and – Must rule out cancer first EMB if not already done) – Can’t be done in >12 week uteri or for women who want fertility – Discuss surgical options for bleeding refractory to medical management. Heavy, irregular bleeding Case 2: Is it the fibroids? Fibroid Symptoms Same history as Case 1 except she has fibroids….On • Bleeding examination her uterus is 16 weeks’ size – Usually normal or menorrhagia (heavy but regular). Fibroids stretch • Very common 80% of hysterectomy specimens (done endometrium= more bleeding for any reason) and ~75% have on U/S at age 50 – Occasionally menometrorrhagia if • About 50% are asymptomatic submucous or intracavitary (Fibroids distort endometrium so it • Grow slowly until menopause and then decrease by can’t be stable) ~50% (can still cause bleeding post‐menopause) • Pressure (not pain) • Dysmenorrhea Heavy, regular bleeding
Load more

Recommended publications
  • The Male Reproductive System
    Management of Men’s Reproductive 3 Health Problems Men’s Reproductive Health Curriculum Management of Men’s Reproductive 3 Health Problems © 2003 EngenderHealth. All rights reserved. 440 Ninth Avenue New York, NY 10001 U.S.A. Telephone: 212-561-8000 Fax: 212-561-8067 e-mail: [email protected] www.engenderhealth.org This publication was made possible, in part, through support provided by the Office of Population, U.S. Agency for International Development (USAID), under the terms of cooperative agreement HRN-A-00-98-00042-00. The opinions expressed herein are those of the publisher and do not necessarily reflect the views of USAID. Cover design: Virginia Taddoni ISBN 1-885063-45-8 Printed in the United States of America. Printed on recycled paper. Library of Congress Cataloging-in-Publication Data Men’s reproductive health curriculum : management of men’s reproductive health problems. p. ; cm. Companion v. to: Introduction to men’s reproductive health services, and: Counseling and communicating with men. Includes bibliographical references. ISBN 1-885063-45-8 1. Andrology. 2. Human reproduction. 3. Generative organs, Male--Diseases--Treatment. I. EngenderHealth (Firm) II. Counseling and communicating with men. III. Title: Introduction to men’s reproductive health services. [DNLM: 1. Genital Diseases, Male. 2. Physical Examination--methods. 3. Reproductive Health Services. WJ 700 M5483 2003] QP253.M465 2003 616.6’5--dc22 2003063056 Contents Acknowledgments v Introduction vii 1 Disorders of the Male Reproductive System 1.1 The Male
    [Show full text]
  • Prolactin Level in Women with Abnormal Uterine Bleeding Visiting Department of Obstetrics and Gynecology in a University Teaching Hospital in Ajman, UAE
    Prolactin level in women with Abnormal Uterine Bleeding visiting Department of Obstetrics and Gynecology in a University teaching hospital in Ajman, UAE Jayakumary Muttappallymyalil1*, Jayadevan Sreedharan2, Mawahib Abd Salman Al Biate3, Kasturi Mummigatti3, Nisha Shantakumari4 1Department of Community Medicine, 2Statistical Support Facility, CABRI, 4Department of Physiology, Gulf Medical University, Ajman, UAE 3Department of OBG, GMC Hospital, Ajman, UAE *Presenting Author ABSTRACT Objective: This study was conducted among women in the reproductive age group with abnormal uterine bleeding (AUB) to determine the pattern of prolactin level. Materials and Methods: In this study, a total of 400 women in the reproductive age group with AUB attending GMC Hospital were recruited and their prolactin levels were evaluated. Age, marital status, reproductive health history and details of AUB were noted. SPSS version 21 was used for data analysis. Descriptive statistics was performed to describe the population, and inferential statistics such as Chi-square test was performed to find the association between dependent and independent variables. Results: Out of 400 women, 351 (87.8%) were married, 103 (25.8%) were in the age group 25 years or below, 213 (53.3%) were between 26-35 years and 84 (21.0%) were above 35 years. Mean age was 30.3 years with a standard deviation 6.7. The prolactin level ranged between 15.34 mIU/l and 2800 mIU/l. The mean and SD observed were 310 mIU/l and 290 mIU/l respectively. The prolactin level was high among AUB patients with inter-menstrual bleeding compared to other groups. Additionally, the level was high among women with age greater than 25 years compared to those with age less than or equal to 25 years.
    [Show full text]
  • Endometriosis for Dummies.Pdf
    01_050470 ffirs.qxp 9/26/06 7:36 AM Page i Endometriosis FOR DUMmIES‰ by Joseph W. Krotec, MD Former Director of Endoscopic Surgery at Cooper Institute for Reproductive Hormonal Disorders and Sharon Perkins, RN Coauthor of Osteoporosis For Dummies 01_050470 ffirs.qxp 9/26/06 7:36 AM Page ii Endometriosis For Dummies® Published by Wiley Publishing, Inc. 111 River St. Hoboken, NJ 07030-5774 www.wiley.com Copyright © 2007 by Wiley Publishing, Inc., Indianapolis, Indiana Published by Wiley Publishing, Inc., Indianapolis, Indiana Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permit- ted under Sections 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-646-8600. Requests to the Publisher for permission should be addressed to the Legal Department, Wiley Publishing, Inc., 10475 Crosspoint Blvd., Indianapolis, IN 46256, 317-572-3447, fax 317-572-4355, or online at http:// www.wiley.com/go/permissions. Trademarks: Wiley, the Wiley Publishing logo, For Dummies, the Dummies Man logo, A Reference for the Rest of Us!, The Dummies Way, Dummies Daily, The Fun and Easy Way, Dummies.com, and related trade dress are trademarks or registered trademarks of John Wiley & Sons, Inc., and/or its affiliates in the United States and other countries, and may not be used without written permission.
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • LNG-IUS) in Patients Affected by Menometrorrhagia, Dysmenorrhea and Adenomimyois: Clinical and Ultrasonographic Reports
    European Review for Medical and Pharmacological Sciences 2021; 25: 3432-3439 The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports F. COSTANZI, M.P. DE MARCO, C. COLOMBRINO, M. CIANCIA, F. TORCIA, I. RUSCITO, F. BELLATI, A. FREGA, G. COZZA, D. CASERTA Department of Surgical and Medical Sciences and Translational Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, Italy Abstract. – OBJECTIVE: Adenomyosis is p=0.025; p=0.014). The blood loss decreased the consequence of the myometrial invasion significantly in both the cohorts (p<0.001) and by endometrial glands and stroma. Transvag- particularly in adenomyotic patients. Pain relief inal ultrasonography plays a decisive role in was observed in all the patients (p<0.001). the diagnosis and monitoring of this patholo- CONCLUSIONS: LNG-IUS can be considered gy. Our study aims to evaluate the efficacy of an effective treatment for managing symptoms LNG-IUS (Levonorgestrel Releasing Intrauter- and improving uterine morphology. ine System) as medical therapy. We analyzed both clinical symptoms and ultrasonograph- Key Words: ic aspects of menometrorrhagia and dysmen- Benign disease of uterus, Dysmenorrhea, Gyne- orrhea in patients with adenomyosis and the cologic imaging, Leiomyomas of the uterus/adeno- control group. myosis. PATIENTS AND METHODS: A prospective co- hort study was carried out on 28 patients suf- fering from symptomatic adenomyosis treat- ed with LNG-IUS. Adenomyosis was diagnosed Introduction through transvaginal ultrasonography by an ex- pert sonographer. A control group of 27 symp- Adenomyosis is a benign gynecological dis- tomatic patients (menorrhagia and dysmenor- ease with a large variety of clinical manifestation; rhea) without a transvaginal ultrasonograph- the most frequent include menorrhagia, metror- ic diagnosis of adenomyosis was treated in the rhagia, dysmenorrhea and chronic pelvic pain1.
    [Show full text]
  • Abnormal Uterine Bleeding: a Management Algorithm
    J Am Board Fam Med: first published as 10.3122/jabfm.19.6.590 on 7 November 2006. Downloaded from EVIDENCED-BASED CLINICAL MEDICINE Abnormal Uterine Bleeding: A Management Algorithm John W. Ely, MD, MSPH, Colleen M. Kennedy, MD, MS, Elizabeth C. Clark, MD, MPH, and Noelle C. Bowdler, MD Abnormal uterine bleeding is a common problem, and its management can be complex. Because of this complexity, concise guidelines have been difficult to develop. We constructed a concise but comprehen- sive algorithm for the management of abnormal uterine bleeding between menarche and menopause that was based on a systematic review of the literature as well as the actual management of patients seen in a gynecology clinic. We started by drafting an algorithm that was based on a MEDLINE search for rel- evant reviews and original research. We compared this algorithm to the actual care provided to a ran- dom sample of 100 women with abnormal bleeding who were seen in a university gynecology clinic. Discrepancies between the algorithm and actual care were discussed during audiotaped meetings among the 4 investigators (2 family physicians and 2 gynecologists). The audiotapes were used to revise the algorithm. After 3 iterations of this process (total of 300 patients), we agreed on a final algorithm that generally followed the practices we observed, while maintaining consistency with the evidence. In clinic, the gynecologists categorized the patient’s bleeding pattern into 1 of 4 types: irregular bleeding, heavy but regular bleeding (menorrhagia), severe acute bleeding, and abnormal bleeding associated with a contraceptive method. Subsequent management involved both diagnostic and treatment interven- tions, which often occurred simultaneously.
    [Show full text]
  • Too Much, Too Little, Too Late: Abnormal Uterine Bleeding
    Too much, too little, too late: Abnormal uterine bleeding Jody Steinauer, MD, MAS July, 2015 The Questions • Too much (& too early or too late) – Differential and approach to work‐up – Does she need an endometrial biopsy (EMB)? – Does she need an ultrasound? – How do I stop peri‐menopausal bleeding? – Isn’t it due to the fibroids? • Too fast: She’s hemorrhaging—what do I do? • Too little: A quick review of amenorrhea Case 1 A 46 yo G3P2T1 reports her periods have become 1. What term describes increasingly irregular and heavy her symptoms? over the last 6‐8 months. 2. Physiologically, what Sometimes they come 2 times causes this type of per month and sometimes there bleeding pattern? are 2 months between. LMP 2 3. What is the months ago. She bleeds 10 days differential? with clots and frequently bleeds through pads to her clothes. She occasionally has hot flashes. She also has diabetes and is obese. Q1: In addition to a urine pregnancy test and TSH, which of the following is the most appropriate test to obtain at this time? 1. FSH 2. Testosterone & DHEAS 3. Serum beta‐HCG 4. Transvaginal Ultrasound (TVUS) 5. Endometrial Biopsy (EMB) Terminology: What is abnormal? • Normal: Cycle= 28 days +‐ 7 d (21‐35); Length=2‐7 days; Heaviness=self‐defined • Too little bleeding: amenorrhea or oligomenorrhea • Too much bleeding: Menorrhagia (regular timing but heavy (according to patient) OR long flow (>7 days) • Irregular bleeding: Metrorrhagia, intermenstrual or post‐ coital bleeding • Irregular and Excessive: Menometrorrhagia • Preferred term for non‐pregnant bleeding issues= Abnormal Uterine Bleeding (AUB) – Avoid “DUB” ‐ dysfunctional uterine bleeding.
    [Show full text]
  • Selected Topics in WOMEN’S HEALTH
    www.bpac.org.nz keyword: womenshealth Selected topics in WOMEN’S HEALTH Laboratory investigation of amenorrhoea Polycystic ovary syndrome An overview of dysfunctional uterine bleeding Perimenopause and menopause Sexual dysfunction - loss of libido 8 | September 2010 | best tests Amenorrhoea Amenorrhoea is the absence of menstruation flow. It can Causes of primary amenorrhoea2 be classified as either primary or secondary,1 relative to menarche: ■ Hypergonadotropic hypogonadism/primary hypogonadism/gonadal failure: ■ Primary amenorrhoea: absence of menses by age 16 years in a female with appropriate development – Abnormal sex chromosomes e.g. Turner of secondary sexual characteristics; or absence syndrome of menses by age 13 years and no other pubertal – Normal sex chromosomes e.g. premature maturation2 ovarian failure ■ Secondary amenorrhoea: lack of menses in a ■ Hypogonadotropic hypogonadism/secondary previously menstruating, non-pregnant female, for hypogonadism: 2 greater than six months – In many cases this may be due to a familial delay in puberty and growth. Other causes include congenital abnormalities Primary amenorrhoea e.g. isolated GnRH deficiency, acquired Key messages: lesions, endocrine disturbance, tumour, systemic illness or eating disorder. ■ The most common cause of primary amenorrhoea in a female with no secondary sexual characteristics ■ Eugonadism: is a constitutional delay in growth and puberty. – Anatomic e.g. congenital absence of the In the first instance, watchful waiting is the most uterus and vagina, intersex
    [Show full text]
  • Module 3: Reproductive Tract Infections
    Reproductive Tract Infections Reproductive Health Epidemiology Series Module 3 2003 Department of Health and Human Services REPRODUCTIVE TRACT INFECTIONS REPRODUCTIVE HEALTH EPIDEMIOLOGY SERIES: MODULE 3 June 2003 The United States Agency for International Development (USAID) provided funding for this project through a Participating Agency Service Agreement with CDC (936-3038.01). REPRODUCTIVE HEALTH EPIDEMIOLOGY SERIES—MODULE 3 REPRODUCTIVE TRACT INFECTIONS Divya A. Patel, MPH Nancy M. Burnett, BS Kathryn M. Curtis, PhD Technical Editors Susan Hillis, PhD Polly Marchbanks, PhD U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion Division of Reproductive Health Atlanta, Georgia, U.S.A. 2003 CONTENTS Learning Objectives .........................................................................................1 Overview of Reproductive Tract Infections (RTIs) ............................................3 Prevalence of RTIs .......................................................................................3 What Are the Most Commonly Occurring RTIs in Developing Countries? ....4 Sequelae of Untreated RTIs .........................................................................4 How Are RTIs Transmitted? ........................................................................7 How Are RTIs and Their Sequelae Linked With Key Health-Related Development Programs? ...............................................8 General Model of the Epidemiology
    [Show full text]
  • Abnormal Uterine Bleeding Sorting It All
    Abnormal Uterine Bleeding- Sorting It All Out Patricia Geraghty MSN, FNP-BC, WHNP Disclosures • Abbvie Inc. Speakers Bureau, Advisory Board • Therapeutics MD Speaker, Advisory Board • Sharecare Inc. Advisory Board • No commercial material is included in this presentation. All citations are from peer-reviewed academic sources. The speaker has not been paid by any outside entity for this presentation or any presentation on this topic. Objectives • Define the variation in normal uterine bleeding. • Distinguish the etiology of abnormal uterine bleeding according to the PALM-COEIN classification system. • Determine age appropriate approach to the diagnostic work- up of abnormal uterine bleeding. • Select the management strategies for specific abnormal bleeding etiology utilizing an understanding of structural and hormonal interventions. • Differentiate the interventions for acute heavy uterine bleeding. Defining Normal • Normal menses (95% of population)1 • Frequency every 24 to 38 days • Duration 4 to 6 days • Blood volume 20-80 cc; requires change of protection every 3 to 6 hours on heaviest day(s) • Tapers over following days • 50% volume loss is vaginal and cervical secretions • Regular -difference between longest and shortest interval < 20 days in 12 month period 1Fraser I, et al. Fertil Steril. 2007;87(3):466-476. ACOG Committee Practice Bulletin. Ob Gyn. 2012; 120(1):197-206. Sharp HT, Johnson JV et al. Obstet Gynecol. 2017 Apr;129(4):603-607 Updating Terminology Dimension < 5th Percentile 5th-95th Percentile >95th Percentile Regularity cycle- Absent Regular (variation Irregular (typical variation to-cycle over 12 Amenorrhea 2 ± 20d) >20d between mos longest/shortest interval) Intermenstrual Frequency Infrequent (>38d) Normal Frequent (<24d) Oligomenorrhea Polymenorrhea Duration Shortened (< 4.5d) Normal Prolonged (> 8d) Hypomenorrhea Hypermenorrhea Volume Light (< 5 cc) Normal Heavy (> 80 cc) Hypomenorrhea Menorrhagia Combination Irregular and Heavy Menometrorrhagia Sharp HT, Johnson JV et al.
    [Show full text]
  • Common Reproductive Issues
    CHAPTER4 Izzy, a 27-year-old, presents to COMMON REPRODUCTIVE ISSUES her health care provider complain- ing of progressive severe pelvic KEY TERMS pain associated with her monthly abortion diaphragm menopause abstinence dysfunctional uterine oral contraceptives periods. She has to take off work amenorrhea bleeding (DUB) premenstrual syndrome basal body temperature dysmenorrhea (PMS) and “dope myself up” with pills to (BBT) emergency contraception Standard Days Method cervical cap (EC) (SDM) endure the pain. In addition, she cervical mucus ovulation endometriosis sterilization method fertility awareness symptothermal method has been trying to conceive for over coitus interruptus implant transdermal patch condoms infertility tubal ligation a year without any luck. contraception lactational amenorrhea vaginal ring contraceptive sponge method (LAM) vasectomy Depo-Provera Lunelle injection LEARNING OBJECTIVES Upon completion of the chapter the learner will be able to: 1. Define the key terms used in this chapter. 2. Examine common reproductive concerns in terms of symptoms, diag- nostic tests, and appropriate interventions. 3. Identify risk factors and outline appropriate client education needed in common reproductive disorders. 4. Compare and contrast the various contraceptive methods available and their overall effectiveness. 5. Explain the physiologic and psychological aspects of menopause. 6. Delineate the nursing management needed for women experiencing common reproductive disorders. When women bare their souls to us, we must respond without judgment. 2 CHAPTER 4 COMMON REPRODUCTIVE ISSUES 3 Good health throughout the life cycle begins with the BOX 4.1 Menstrual Disorder Vocabulary individual. Women today can expect to live well into their 80s and need to be proactive in maintaining their own • Meno = menstrual-related quality of life.
    [Show full text]
  • Abnormal Uterine Bleeding: and Gynecology, Florida Hospital Graduate Avoid the Rush to Hysterectomy Medical Education, Orlando, Fla
    THE JOURNAL OF FAMILY PRACTICE D. Ashley Hill, MD Department of Obstetrics Abnormal uterine bleeding: and Gynecology, Florida Hospital Graduate Avoid the rush to hysterectomy Medical Education, Orlando, Fla. d.ashley.hill.md@fl hosp.org Patients with heavy bleeding may think hysterectomy is their only recourse, but research supports other alternatives. Practice recommendations several occasions. She says she often feels • The levonorgestrel-IUS is the tired, and worries that she may be ane- most effective treatment for heavy mic. Preserving fertility is not a concern; menstrual bleeding, reducing blood her husband has had a vasectomy. loss by close to 100%® Dowden (A). HealthOn Media exam she is without orthostasis and appears well. Her uterus is top- • Endometrial ablation is an effective normal size, nontender, and there are Copyrighttreatment forFor women personal who want to use noonly adnexal masses or cervical or vaginal avoid major surgery and preserve abnormalities. You note a normal Pap at their uterus, but have no wish to your offi ce 5 months ago. Her offi ce he- become pregnant in the future (A). moglobin is 9.8 mg/dL. IN THIS ARTICLE She asks you to refer her to a gyne- ❚ What a difference • Endometrial biopsy should be part cologist for a hysterectomy because she of the evaluation of abnormal uterine “just can’t take it anymore.” Her heavy saline can make: bleeding in all women over age 35 (B). menses are disrupting her life. Since she 2 sonograms does not want any more children, she Page 139 Strength of recommendation (SOR) feels that if someone could “just take it A Good-quality patient-oriented evidence out,” her problem would be solved.
    [Show full text]